BPS-314d-MR 2018-01-08T14:58:12+00:00

Clinical Trials

April 19, 2014

A multi-center, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added-on to treprostinil inhaled (Tyvaso) in subjects with pulmonary arterial hypertension

  • Study Sponsor: Lung Biotechnology Inc. (subsidiary of United Therapeutics)
  • Start Date: 06/2013
  • End Date: Active, not recruiting
  • Design: Placebo-controlled – Background treatment allowed
  • Age range (years): from 18 to 80
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • HIV – APAH
    • Anorexigen/Toxin – APAH
    • PAH associated with repaired congenital systemic-to-pulmonary shunts (repaired for 1 or more years)
  • Study Duration for individual patient: 1-3 years
  • Contact: Tracy Newbold (tnewbold@lungbiotechnology.com)
  • Listing on clinicaltrials.gov